Amgen

FDA Shakeup: Høeg's Departure and Amgen Drug Controversy

FDA · 5 min

The FDA's dismissal of acting CDER director Tracy Høeg and the revelation of 20 patient deaths linked to Amgen's Tavneos in Japan create a dual crisis of regulatory leadership and drug safety. This analysis provides key takeaways, a timeline of events, and strategic implications for pharmaceutical BD and regulatory teams.

Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors

FDA · neurology · 8 min

Recent leadership transitions at Amgen and Zai Lab signal potential shifts in strategic direction and operational focus. Understanding these changes is crucial for pharmaceutical business development, investment, and regulatory teams.

Amgen's CFO Transition: Implications for Pharma Investments

3 min

Amgen bids farewell to its CFO and attracts a Galderma executive with a significant bonus. This article explores the implications for the pharma industry.

Amgen's CFO Departure and Galderma's Strategic Move

3 min

Amgen's CFO is retiring, and the company has recruited a Galderma executive with a significant bonus. This article explores the implications for the pharmaceutical landscape.

Amgen's CFO Departure and Galderma's New Executive: What It Means for Pharma

2 min

Amgen bids farewell to its CFO, attracting a Galderma executive with a substantial bonus. This article explores the implications for the pharmaceutical industry.

Amgen's Expanded Crackdown on 340B Program Misuse

3 min

Amgen has intensified its efforts to address what it claims is the misuse of the 340B program. This article explores the implications for the pharmaceutical sector.

Amgen's 340B Program Crackdown: Implications for Pharma

3 min

Amgen has intensified its efforts against perceived misuse of the 340B program. This article explores the implications for pharmaceutical companies and stakeholders.